Focus: Genetix Biotherapeutics is a private gene therapy specialist headquartered in Somerville, MA, focusing on cellular extraction and lentiviral-mediated reintroduction for rare blood and neurological diseases. The company operates a robust clinical pipeline spanning Phase 1–3 programs in sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
9 added, 6 removed. Backfill posture.
A high-risk, high-reward opportunity for scientists and regulators betting on gene therapy validation in monogenic blood disorders, but with meaningful financial and operational clarity gaps that warrant due diligence on funding runway and ownership changes.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Genetix Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Genetix Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
A year after distressed buyout, what’s become of Somerville’s Bluebird Bio? - The Boston Globe
A year after distressed buyout, what’s become of Somerville’s Bluebird Bio? The Boston Globe
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two - Reuters
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two Reuters
SPIMACO and Genetix Biotherapeutics Sign Agreement to Manufacture LYFGENIA™ and ZYNTEGLO™ in Saudi Arabia and Middle East - وكالة الأنباء السعودية
SPIMACO and Genetix Biotherapeutics Sign Agreement to Manufacture LYFGENIA™ and ZYNTEGLO™ in Saudi Arabia and Middle East وكالة الأنباء السعودية
Genetix Biotherapeutics Inc. and Saudi Pharmaceutical Industries and Medical Appliances Corporation Announce Strategic Agreement to Commercialize and Manufacture Lyfgenia? and Zynteglo? in Saudi Arabia and the Broader Middle East Region - marketscreener.com
Genetix Biotherapeutics Inc. and Saudi Pharmaceutical Industries and Medical Appliances Corporation Announce Strategic Agreement to Commercialize and Manufacture Lyfgenia? and Zynteglo? in Saudi Arabia and the Broader Middle East Region marketscreener.com
Genetix Biotherapeutics and SPIMACO Announce Strategic Agreement to Commercialize and Manufacture LYFGENIA™ & ZYNTEGLO™ in Saudi Arabia and the Broader Middle East Region - Business Wire
Genetix Biotherapeutics and SPIMACO Announce Strategic Agreement to Commercialize and Manufacture LYFGENIA™ & ZYNTEGLO™ in Saudi Arabia and the Broader Middle East Region Business Wire
MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies - Yahoo Finance Singapore
MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies Yahoo Finance Singapore
Showing 6 of 9 news items
Based on last 4 crawl cycles
No current FDA warnings or active layoff filings, but private status and recent M&A chatter warrant confirmation of post-acquisition integration stability and decision-making continuity.
Recent peer-reviewed publications with author affiliations at this company